Evidence map›Paper›PMID 36701644›Full record

Trial reportOcular immunology and inflammation2024

Reduced Dose Methotrexate and Mycophenolate Mofetil in Noninfectious Uveitis: A Sub-Analysis from the First-Line Antimetabolites as Steroid Sparing Therapy (FAST) Trial.

Amol A Sura, Yuwei Sun, Amit K Reddy, S R Rathinam, John A Gonzales, Radhika Thundikandy, Rajesh Vedhanayaki, Anuradha Kanakath, Bala Murugan, Thuy A Doan and 5 more

Registry-linked trialOpen access · greenAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Ocular immunology and inflammation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01829295 (First-line Antimetabolites as Steroid-sparing Treatment), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01829295 phase3completednot on this map

First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial

TypeinterventionalSponsorUniversity of California, San FranciscoRan2013 to 2018Enrolled216ConditionsUveitisArmsMycophenolate mofetil, Methotrexate, Prednisone
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 4 countries.

Amol A SuraFrancis I. Proctor Foundation, University of California San Francisco, San Francisco, California, USA.
Yuwei SunFrancis I. Proctor Foundation, University of California San Francisco, San Francisco, California, USA.
Amit K ReddyFrancis I. Proctor Foundation, University of California San Francisco, San Francisco, California, USA.
S R RathinamUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India.
John A GonzalesFrancis I. Proctor Foundation, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0003-0558-9793
Radhika ThundikandyUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India.
Rajesh VedhanayakiUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Madurai, India.
Anuradha KanakathUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Coimbatore, India.
Bala MuruganUvea Services, Aravind Eye Hospitals and Postgraduate Institute of Ophthalmology, Pondicherry, India.
Thuy A DoanFrancis I. Proctor Foundation, University of California San Francisco, San Francisco, California, USA.ORCID 0000-0003-2733-8370
Lyndell L LimCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
Eric B SuhlerCasey Eye Institute, Oregon Health and Science University, OHSU-PSU School of Public Health, and Portland Veterans' Affairs Health Care System, Portland, Oregon, USA.
Hassan A Al-DhibiDivision of Vitreoretinal Surgery and Uveitis, King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia.
Nisha R AcharyaFrancis I. Proctor Foundation, University of California San Francisco, San Francisco, California, USA.
FAST Research Group
University of California, San Francisco · USAravind Eye Hospital · INCentre for Eye Research Australia · AUKing Khaled Eye Specialist Hospital · SAOregon Health & Science University · US

Funding

First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis TrialU10EY021125 · NEI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ACHARYA, NISHA · 2012 to 2016
$4.6M
NEI NIH HHS U10 EY021125
6 · The paper itself

Abstract

purposeSome patients taking methotrexate (MTX) or mycophenolate mofetil (MMF) experience intolerable side effects at full doses. We evaluated whether dose reduction affected treatment outcomes in uveitis patients.

methodsSubanalysis of the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial. Patients were randomized to receive MTX (25 mg weekly) or MMF (3 g daily). A pre-specified dose reduction protocol could be employed for intolerable side effects. Primary analysis was performed at 6 months.

results43/194 patients (22%) required dose reduction. 88/151 patients (58%) on maximum doses and 32/43 patients (74%) on reduced doses were deemed treatment successes at 6 months. The odds ratio point estimate (1.60, 95% CI 0.72-3.74) favored dose-reduction but this was not significant. Following reduction, adverse events improved at the subsequent study visit (79 events reduced to 63 events).

conclusionDose reduction of antimetabolites was not associated with worse outcomes in this subanalysis of a uveitis trial.

Indexed as

Dose-Response Relationship, DrugImmunosuppressive AgentsMethotrexateMycophenolic AcidUveitisAdultDouble-Blind MethodFemaleFollow-Up StudiesGlucocorticoidsHumansMaleMiddle AgedTreatment OutcomeVisual AcuityGlucocorticoidsImmunosuppressive AgentsMethotrexateMycophenolic AcidAntimetabolitedosingmethotrexatemycophenolate mofetiluveitis

Identifiers

PMID36701644
PMCPMC10368793
OpenAlexW4318263848

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.